• Aclacinomycin A and Persistent rDNA Damage

  2026-09-26

  Aclacinomycin A offers a useful way to investigate how topoisomerase-linked DNA stress intersects with nucleolar damage responses. This article connects its established cytotoxic mechanisms to evidence on persistent ribosomal DNA lesions and PML-nucleolar associations, while outlining experiments that can test the connection without assuming it.

• CA-074 Me for Lysosomal and Necroptosis Assays

  2026-09-25

  Use CA-074 Me to test whether intracellular cathepsin B contributes to lysosomal damage and cell death—not merely to measure a general loss of viability. This guide connects a mechanistic necroptosis study with practical inhibitor controls, live-cell readouts, and troubleshooting for cell-based and inflammation research.

• Self-Amplifying RNA Improves Influenza B Vaccine Responses

  2026-09-25

  This study compares nucleoside-modified mRNA, self-amplifying RNA, and circular RNA vaccine approaches for seasonal influenza. In mouse challenge experiments, a low-dose trivalent self-amplifying RNA vaccine generated durable antibody responses and protected against influenza B, addressing a weakness observed with the tested mRNA vaccine.

• 5-Azacytidine and the Biology of Tumor Dormancy

  2026-09-24

  5-Azacytidine is best known as a DNA demethylation agent, but its effects can extend beyond tumor-cell killing. Explore how a 5-AzaC combination study reframes epigenetic treatment as a way to establish metastatic-cell dormancy—and how to design experiments that distinguish dormancy from cytotoxicity.

• 5-Azacytidine Workflows for Viral Mimicry Research

  2026-09-24

  Learn how to use 5-Azacytidine to probe DNA methylation, gene reactivation, and viral-mimicry responses—with a practical workflow grounded in recent PTEN-deficient glioblastoma research. The article distinguishes reported findings from suggested pilot conditions and explains how to control for cytotoxicity and combination-treatment effects.

• GSH-Responsive MOF Nanoparticles for Melanoma Therapy

  2026-09-23

  Hao and colleagues developed a glutathione-responsive metal–organic framework nanoparticle carrying indocyanine green and the PD-1/PD-L1-blocking peptide AUNP12. In the reported design, near-infrared photothermal treatment is paired with checkpoint inhibition to connect tumor-cell damage with immune activation; the findings support further study while leaving important formulation and translation questions open.

• Cisplatin A8321: Reliable Assay Workflows

  2026-09-23

  This scenario-driven guide shows how Cisplatin (SKU A8321) can support controlled viability, apoptosis, and chemotherapy resistance studies. It combines product-handling data with recent evidence on cisplatin-resistant lung adenocarcinoma models to improve interpretation and day-to-day laboratory reproducibility.

• Oseltamivir acid Research Workflow Guide

  2026-09-22

  Build more reliable influenza neuraminidase assays with Oseltamivir acid, from fresh-solution handling to resistance-aware viral readouts. The workflow also shows how human-relevant exposure studies and carefully controlled breast-cancer models can extend interpretation beyond a single antiviral endpoint.

• Etomoxir as a Translational Tool for Immunometabolism

  2026-09-22

  Etomoxir is more than a fatty acid oxidation inhibitor: it is a strategic perturbation tool for connecting mitochondrial substrate use with immune-cell function. This thought-leadership article explains how to use Etomoxir and R-(+)-Etomoxir in standardized whole-blood assays, interpret concentration-dependent pharmacology, compare experimental platforms, and build a translational path toward metabolic disorder research and neuroinflammation research.

• O-GlcNAc, HUWE1, and Ferroptosis in Preeclampsia

  2026-09-21

  The reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway that links placental protein modification to iron handling, ferroptosis, and trophoblast syncytialization in preeclampsia. Its combination of modification proteomics, mechanistic validation, and mouse studies provides a framework for testing how OGT-dependent signaling influences placental stress.

• FXR Phase Separation Clusters Coronavirus Organelles

  2026-09-21

  Li et al. show that fragile X–related proteins organize β-coronavirus double-membrane vesicles through liquid–liquid phase separation, linking replication-organelle architecture to local translation and SARS-CoV-2 replication. The study combines cellular perturbation, membrane reconstitution, condensate assays, and infection experiments to define FXR proteins as host factors that spatially concentrate viral replication machinery.

• Lisinopril dihydrate: ACE Inhibition Workflows

  2026-09-20

  Lisinopril dihydrate provides a practical, water-compatible probe for connecting ACE target engagement with hypertension, cardiac injury, and renal disease phenotypes. This guide emphasizes concentration-range design, peptidase selectivity controls, solution handling, and troubleshooting for more reproducible translational experiments.

• Measuring Cancer Drug Response Beyond Viability

  2026-09-19

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent dimensions of anticancer drug response. This framework helps researchers design in vitro studies that separate proliferative arrest from cytotoxicity and interpret response timing more rigorously.

• Pravastatin Sodium: From Mechanism to Translation

  2026-09-18

  Pravastatin sodium is more than a familiar lipid-lowering tool. Its selective HMG-CoA reductase inhibition, macrophage activity, and transporter-dependent hepatocyte handling create a practical framework for translational studies spanning cholesterol biology, metabolic disease, and carefully bounded exploratory oncology research.

• FDA-Approved Drug Screen Finds MERS-CoV Inhibitors

  2026-09-18

  de Wilde and colleagues screened 348 FDA-approved compounds in cell culture and identified four molecules, including Lopinavir, that inhibited MERS-CoV replication at low-micromolar concentrations. The study provides a practical repurposing framework for emerging coronavirus research while showing why cell-based antiviral activity must be separated from claims about mechanism, clinical efficacy, or coronavirus-specific drug development.

8019 records 1/535 page Next 12345 下5页 Last page